We've found
12,064 Hematology
clinical trials
Hematology, Oncology Clinical Trial
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Recurrent Plasma Cell Myeloma Clinical Trial
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 2/3/2016
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Cancer Indications
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Acquired Hemophilia A Clinical Trial
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Status: Enrolling,
Phase
Updated: 3/22/2018
Click here to add this to my saved trials
Myeloid and Monocytic Leukemia Clinical Trial
CAMELLIA: Anti-CD47 Antibody Therapy in Relapsed/Refractory Acute Myeloid Leukaemia
Status: Enrolling,
Phase
I
Updated: 2/4/2016
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Status: Enrolling,
Phase
I
Updated: 7/24/2017
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Status: Enrolling,
Phase
I
Updated: 7/24/2017
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
BAX 855 Previously Untreated Patient (PUP)
Status: Enrolling,
Phase
III
Updated: 4/19/2018
Click here to add this to my saved trials
Hemophilia A Clinical Trial
BAX 855 Previously Untreated Patient (PUP)
Status: Enrolling,
Phase
III
Updated: 4/19/2018
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
The Oronasal Microbiota in Pediatric Oncology Patients
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Graft vs Host Disease Clinical Trial
Study of PRO 140 for Prophylaxis of Acute GVHD in Patients Undergoing RIC Allogenic Stem-Cell Transplantaton
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology Clinical Trial
A Randomized Multicenter Study for Isolated Skin Vasculitis
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Plasma Cell Myeloma Clinical Trial
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Smoldering Multiple Myeloma Clinical Trial
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Homocystinuria Due to CBS Deficiency Clinical Trial
Natural History Study of Cystathionine Beta-synthase Deficiency Homocystinuria (CBSDH)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Homocystinuria Due to CBS Deficiency Clinical Trial
Natural History Study of Cystathionine Beta-synthase Deficiency Homocystinuria (CBSDH)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Homocystinuria Due to CBS Deficiency Clinical Trial
Natural History Study of Cystathionine Beta-synthase Deficiency Homocystinuria (CBSDH)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Reproductive Clinical Trial
Molecular Determinants of Coronaruy Artery Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
AML Clinical Trial
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
SEL24/MEN1703 in Patients With Acute Myeloid Leukemia
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Previously Untreated Acute Myeloid Leukemia Clinical Trial
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Alphanate in Immune Tolerance Induction Therapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MMRF Molecular Profiling Protocol
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MMRF Molecular Profiling Protocol
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MMRF Molecular Profiling Protocol
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MMRF Molecular Profiling Protocol
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
Status: Enrolling,
Phase
Updated: 3/26/2018
Click here to add this to my saved trials
Hemophilia A Clinical Trial
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
Status: Enrolling,
Phase
Updated: 3/26/2018
Click here to add this to my saved trials
We've found
12,064 Hematology
clinical trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Recurrent Plasma Cell Myeloma Clinical Trial
Updated: 2/3/2016
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 2/3/2016
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Cancer Indications
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Acquired Hemophilia A Clinical Trial
Updated: 3/22/2018
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Status: Enrolling,
Phase
Updated: 3/22/2018
Click here to add this to my saved trials
Myeloid and Monocytic Leukemia Clinical Trial
Updated: 2/4/2016
CAMELLIA: Anti-CD47 Antibody Therapy in Relapsed/Refractory Acute Myeloid Leukaemia
Status: Enrolling,
Phase
I
Updated: 2/4/2016
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 7/24/2017
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Status: Enrolling,
Phase
I
Updated: 7/24/2017
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 7/24/2017
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Status: Enrolling,
Phase
I
Updated: 7/24/2017
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Updated: 12/31/1969
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Updated: 12/31/1969
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Updated: 12/31/1969
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Updated: 12/31/1969
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Updated: 12/31/1969
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Updated: 12/31/1969
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Updated: 12/31/1969
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Updated: 12/31/1969
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Updated: 12/31/1969
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Updated: 12/31/1969
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Updated: 12/31/1969
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 4/19/2018
BAX 855 Previously Untreated Patient (PUP)
Status: Enrolling,
Phase
III
Updated: 4/19/2018
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 4/19/2018
BAX 855 Previously Untreated Patient (PUP)
Status: Enrolling,
Phase
III
Updated: 4/19/2018
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
The Oronasal Microbiota in Pediatric Oncology Patients
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Updated: 12/31/1969
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Updated: 12/31/1969
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Updated: 12/31/1969
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Updated: 12/31/1969
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Updated: 12/31/1969
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Updated: 12/31/1969
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Updated: 12/31/1969
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Graft vs Host Disease Clinical Trial
Updated: 12/31/1969
Study of PRO 140 for Prophylaxis of Acute GVHD in Patients Undergoing RIC Allogenic Stem-Cell Transplantaton
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Updated: 12/31/1969
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology Clinical Trial
Updated: 12/31/1969
A Randomized Multicenter Study for Isolated Skin Vasculitis
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Updated: 12/31/1969
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Plasma Cell Myeloma Clinical Trial
Updated: 12/31/1969
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Smoldering Multiple Myeloma Clinical Trial
Updated: 12/31/1969
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Homocystinuria Due to CBS Deficiency Clinical Trial
Updated: 12/31/1969
Natural History Study of Cystathionine Beta-synthase Deficiency Homocystinuria (CBSDH)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Homocystinuria Due to CBS Deficiency Clinical Trial
Updated: 12/31/1969
Natural History Study of Cystathionine Beta-synthase Deficiency Homocystinuria (CBSDH)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Homocystinuria Due to CBS Deficiency Clinical Trial
Updated: 12/31/1969
Natural History Study of Cystathionine Beta-synthase Deficiency Homocystinuria (CBSDH)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Reproductive Clinical Trial
Updated: 12/31/1969
Molecular Determinants of Coronaruy Artery Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
AML Clinical Trial
Updated: 12/31/1969
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
SEL24/MEN1703 in Patients With Acute Myeloid Leukemia
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Previously Untreated Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Updated: 12/31/1969
Alphanate in Immune Tolerance Induction Therapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
MMRF Molecular Profiling Protocol
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
MMRF Molecular Profiling Protocol
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
MMRF Molecular Profiling Protocol
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
MMRF Molecular Profiling Protocol
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Updated: 12/31/1969
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Updated: 12/31/1969
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Updated: 12/31/1969
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Updated: 12/31/1969
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Updated: 12/31/1969
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Updated: 12/31/1969
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 3/26/2018
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
Status: Enrolling,
Phase
Updated: 3/26/2018
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 3/26/2018
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
Status: Enrolling,
Phase
Updated: 3/26/2018
Click here to add this to my saved trials